Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine + Acalabrutinib in CLL
NCT05971251Phase 1Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of loncastuximab tesirine in chronic lymphocytic leukemia (CLL) (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Maximum Tolerated Dose at 12 months and Dose-Limiting Toxicity at 42 days. Started Dec 2023; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05971251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05971251.